Health - Reaching Every Child

Home

Reaching Every Child

By KENT HILL

A powerful alliance of governments, international organizations and public health institutions funds programs that strengthen health and immunization systems, saving young lives.

For more than half a century, medical science has recognized that widespread, routine immunization against infectious diseases can prevent the deaths of young children, sparing parents an agony that has spanned millennia. When children escape disease, they can thrive to become healthy adults, contributing to the development of more vibrant and productive societies.

Knowledge is one thing. The delivery of vaccine to children everywhere is a vastly greater challenge. Since the 1970s, the U.S. Agency for International Development (USAID) has worked with partners across the globe to confront that challenge and help immunize children in remote and underdeveloped parts of the world. Over the decades, tens of millions of infants and children have survived the momentary discomfort and dismay of immunization to gain protection from disease.

USAID was a partner in the 1970s campaign to rid the world of smallpox. USAID provided support in the 1980s to the World Health Organization's (WHO) Expanded Programme on Immu-nization, a campaign to increase access to immunization against childhood tuberculosis, polio, diphtheria, pertussis, tetanus and measles. By 1990, coverage for those six diseases reached 70 percent globally, and the occurrence of those preventable but often fatal illnesses fell dramatically. Even though the news was fairly good at the global level, most of Africa and Asia remained far below the global mark of 70 percent-clearly a problem that needed attention.

We have learned that the challenge never ends and the task is never done.

In the 1990s, the levels of vaccination among populations leveled off and even declined in some nations. The momentum of the WHO program slowed for a variety of reasons, not the least of which was a sense that the job was done. In economically struggling nations, other priorities demanded attention. Major donors turned their attention to other desperate problems.

By 1999, recognition of this reversal of progress led to a new initiative-the formation of the Global Alliance for Vaccines and Immunization (http://www.gavialliance.org/). It is an alliance devoted to saving children's lives and protecting people's health through the widespread use of vaccines. A powerful alliance of governments, international organizations, vaccine manufacturers, nongovernmental organizations and public health institutions is devoted to creating a new model for the delivery of international development aid. In pursuit of that goal, the alliance funds programs that strengthen health and immunization systems and accelerate access to new vaccines and new vaccine technologies.

Donors have committed more than $3 billion to the alliance fund, and more than $1 billion has already been distributed to nations implementing immunization programs. The fund has provided multiyear grants to 73 of the world's poorest countries in order to help them build a permanent and sustainable system for delivery of immunizations to children.
The United States continues to be one of the largest donors to the alliance, having committed more than $350 million since the institution was created.

In its first five years, almost 100 million additional children received new vaccines, with 2006 efforts reaching another 38 million youngsters. WHO estimates that the premature deaths of 2.3 million children have been prevented through the efforts of the alliance. By reaching so many children in such a short time, the alliance is amplifying its global impact and paving the way for the introduction of future vaccines.

The alliance now enters a new phase in which we will work toward broader goals to increase global development assistance for health, harmonize the work of the partners with strategies devised by recipient countries, and advance new, better and more affordable technologies for the delivery of immunizations and health care.

Considerable success has already been achieved in improving the number of children reached with vaccines. In fact, effective and easy-to-use technologies have been important in the scale-up of developing world vaccination rates in the alliance's first few years. For example, a vaccine against hepatitis B had been available and used for more than 15 years in the developed world before the Global Alliance program came into existence. With financial backing from its partners, the alliance moved swiftly to make hepatitis B vaccines available for use in developing countries. The new hepatitis B vaccine reached more than 90 million infants in five years. In addition, the alliance was influential in encouraging vaccine manufacturers to combine hepatitis B vaccine with the established vaccine against diphtheria, typhoid and pertussis (DTP), allowing immediate inclusion of the new product into existing delivery systems. We are now seeing the fruits of those efforts as new suppliers have entered that market, resulting in substantial price reductions for poor countries.

For years, USAID supported the development and promotion of a special type of syringe known as the auto-disable that is quick, convenient and safe. It can be used only once, thus reducing the danger that immunization could expose patients to HIV or other diseases through syringe reuse. The vaccination alliance purchased these devices by the tens of millions to allow a wide introduction of these safe syringes into immunization programs in the world's poorest countries. Enough syringes were provided for each country program for three years, and now all countries have taken on the cost of those syringes for routine use in their immunization programs.

The alliance has also had a positive influence on the global business of vaccine production by demonstrating to manufacturers that the developing world can be a profitable market. This activity has thus stimulated additional vaccine supply and reduced prices of some of the funded vaccines in a timely manner, compared to historical trends. In the past, broad adoption of a new vaccine in poorer nations has lagged as much as 15 to 20 years behind developed nations. In November 2006, the alliance board approved proposals allowing distribution of much newer vaccines, introduced in recent years in the United States and Europe, that will combat diseases that kill 1.5 million children annually. One new vaccine targets rotavirus, which causes severe and often fatal diarrhea, and the second prevents pneumococcus, a major cause of pneumonia, meningitis and sepsis.

The two vaccines will be introduced on a staggered scale in a limited number of countries at first to ensure the completion of additional efficacy studies.

Meanwhile, USAID has independently supported a number of parallel initiatives. For example, it has backed research to create vaccine-vial monitors, which allow vaccines to remain safely outside the cold chain for limited periods of time. This is an important advancement for teams attempting to deliver vaccines to remote villages where refrigeration does not exist or is difficult to maintain in transit.

Current and future research supported by USAID is devoted to development of a vaccine against HIV/AIDS that will be appropriate for use against developing world strains of the disease and under the prevailing conditions of those areas. The United States is also investing in research to develop a vaccine against malaria, a disease that is rare in the developed world but still takes a million lives in the developing world each year, 75 percent of whom are African children. A vaccine against malaria becomes an ever more critical need with the proliferation of malaria strains resistant to most known drug therapies.

Even as USAID, the Global Alliance for Vaccines and Immunization and developing world nations muster new resources and ideas on expanding immunization programs to reach every child, we have learned that the rewards of our efforts could be even greater than we dreamed. A 2005 study from the Harvard School of Public Health showed that the benefits of immunization have been significantly underestimated in the past. Not only does immunization protect children from illness and death at an early age, but it also protects the child from the long-term effects of illness on growth and development. Healthier children do better in school and become more productive and higher-earning adults. In fact, the study's authors equate the value of immunization in a child's life with that of primary education.

Ensuring better health for the world's children is a gift our generation must deliver to the future. Kent Hill is the assistant administrator for USAID's Bureau for Global Health and a member of the board of the Global Alliance for Vaccines and Immunization.

Courtesy: SPAN Magazine

Please share your views on this article. Write to editorspan@state.gov

Disclaimer: The views expressed in this health article are strictly those of the writer and 123oye does not take any responsibility for them. Kindly consult a Doctor before following any advice.